Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that Tim M. Mayleben, Esperion’s president and chief executive officer, will present at the BioCentury Newsmakers in the Biotech Industry Conference in New York. Mr. Mayleben’s presentation will take place on Friday, September 27 at 2:00 ET at the Millennium Broadway Hotel and Conference Center.